👉Targeted therapies are expanding treatment options in metastatic thyroid cancer (MTC).
👉In the past 10 years, four VEGF inhibitors have been approved for MTC: sorafenib and lenvatinib for differentiated thyroid cancer, and cabozantinib and vandetanib for medullary thyroid cancer.
👉Cabozantinib and vandetanib are also moderate RET inhibitors.
👉In addition, larotrectinib was recently approved for all solid tumors that harbor TRK fusions, and patients with differentiated thyroid cancer are frequently TRK positive.
👉Consequently, knowing what genetic mutations a patient harbors can greatly affect the choice of therapies.
#Arrangoiz #ThyroidSurgeon #ThyroidExpert #CASO #CenterforAdvancedSurgicalOncology #PalmettoGeneralHospital